For research use only. Not for therapeutic Use.
CT52923 is a selective, orally active platelet-derived growth factor receptor (PDGFR) antagonist. CT52923 also is an ATP-competitive inhibitor. CT52923 can be used for the research variety of pathological diseases, including atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer[1].
CT52923 inhibit the PDGFRs and stem cell factor receptor with an IC50 value of 100 to 200 nM[1].
CT52923 (0.01-30 μM; 24 h) blocks plateletderived growth factor-induced smooth muscle cell migration or fibroblast proliferation with an IC50 of 64 and 280 nM, respectively[1].
CT52923 (oral; 5, 15, 30, and 50 mg/kg; twice daily) can significantly inhibit neointima formation following carotid artery injury by oral administration in the rat[1].
| Catalog Number | I042304 |
| CAS Number | 205256-55-9 |
| Synonyms | N-(1,3-benzodioxol-5-ylmethyl)-4-(6,7-dimethoxyquinazolin-4-yl)piperazine-1-carbothioamide |
| Molecular Formula | C23H25N5O4S |
| Purity | ≥95% |
| InChI | InChI=1S/C23H25N5O4S/c1-29-19-10-16-17(11-20(19)30-2)25-13-26-22(16)27-5-7-28(8-6-27)23(33)24-12-15-3-4-18-21(9-15)32-14-31-18/h3-4,9-11,13H,5-8,12,14H2,1-2H3,(H,24,33) |
| InChIKey | ORRFUYVNMZSYIC-UHFFFAOYSA-N |
| SMILES | COC1=C(C=C2C(=C1)C(=NC=N2)N3CCN(CC3)C(=S)NCC4=CC5=C(C=C4)OCO5)OC |
| Reference | [1]. J C Yu, et al. Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular proliferation, migration, and suppression of neointima following vascular injury. J Pharmacol Exp Ther. 2001 Sep;298(3):1172-8. |
